We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod
Read MoreHide Full Article
Teleflex Incorporated (TFX - Free Report) recently announced the receipt of the FDA clearance for Wattson Temporary Pacing Guidewire. The company will feature Wattson at TVT — The Structural Heart Summit between Jun 7-10 in Phoenix.
The latest development will expand company’s Structural Heart Portfolio with the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV).
More on Wattson Temporary Pacing Guidewire
The Wattson Temporary Pacing Guidewire offers dual functionality, allowing valve delivery and ventricular bipolar pacing during TAVR or BAV treatments. It has a straightforward design to increase procedural efficiency.
The device offers an alternative to the right ventricular pacing procedure that is intended to reduce a number of risks, steps and expenses. The Wattson Temporary Pacing Guidewire is designed with numerous electrodes and a bipolar.
Significance of Wattson Temporary Pacing Guidewire
Using Wattson Temporary Pacing Guidewire, the company can provide doctors a brand-new instrument that was created to address unmet clinical needs that are typically encountered during TAVR or BAV surgeries.
The Wattson Temporary Pacing Guidewire demonstrates Teleflex’s commitment to offering more solutions to further simplify minimalist TAVR and other structural treatments and focus on deliberate innovation.
Industry Prospects
Per a report by Grand View Research, the global structural heart devices market size to be valued at $9.1 billion by 2025 and is expected to witness a CAGR of 9.15%. A rise in incidence of structural heart diseases (aortic stenosis and mitral regurgitation), technological advancements, the development of innovative repair devices — such as annuloplasty rings and occluders — and an increase in the demand for minimally-invasive techniques are factors driving the market.
Recent Developments
In June 2023, Teleflex received FDA 510(k) clearance for the Arrow EZ-IO Needle. The EZ-IO Needle, a critical component of the Arrow EZ-IO Intraosseous Vascular Access System, has a patented diamond tip designed for fast, precise and steady insertion. The EZ-IO System can be used when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases.
Image Source: Zacks Investment Research
In May 20203, Teleflex presented new research findings reinforcing the long-term durability of Prostatic Urethral Lift (PUL) with the UroLift System and lower complication rates compared to other minimally invasive procedures for men with enlarged prostate, also called benign prostatic hyperplasia (BPH).
Price Performance
Shares of the company have dropped 11.2% in the past year compared with the industry’s fall of 4.5%.
Zacks Rank and Key Picks
Teleflex carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Addus Homecare Corporation (ADUS - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Hologic, Inc. (HOLX - Free Report) .
The Zacks Consensus Estimate for Addus Homecare’s 2023 earnings indicates a 10.9% year-over-year growth. The Zacks Consensus Estimate for ADUS’s 2023 earnings has moved 0.5% north in the past 30 days.
Merit Medical reported a first-quarter 2023 adjusted EPS of 64 cents, beating the Zacks Consensus Estimate by 16.4%. Revenues of $297.6 million surpassed the Zacks Consensus Estimate by 5.9%. It currently carries a Zacks Rank #2.
Merit Medical has a long-term estimated growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average being 27.3%.
Hologic has gained 6.9% compared with the industry’s 4.4% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod
Teleflex Incorporated (TFX - Free Report) recently announced the receipt of the FDA clearance for Wattson Temporary Pacing Guidewire. The company will feature Wattson at TVT — The Structural Heart Summit between Jun 7-10 in Phoenix.
The latest development will expand company’s Structural Heart Portfolio with the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV).
More on Wattson Temporary Pacing Guidewire
The Wattson Temporary Pacing Guidewire offers dual functionality, allowing valve delivery and ventricular bipolar pacing during TAVR or BAV treatments. It has a straightforward design to increase procedural efficiency.
The device offers an alternative to the right ventricular pacing procedure that is intended to reduce a number of risks, steps and expenses. The Wattson Temporary Pacing Guidewire is designed with numerous electrodes and a bipolar.
Significance of Wattson Temporary Pacing Guidewire
Using Wattson Temporary Pacing Guidewire, the company can provide doctors a brand-new instrument that was created to address unmet clinical needs that are typically encountered during TAVR or BAV surgeries.
The Wattson Temporary Pacing Guidewire demonstrates Teleflex’s commitment to offering more solutions to further simplify minimalist TAVR and other structural treatments and focus on deliberate innovation.
Industry Prospects
Per a report by Grand View Research, the global structural heart devices market size to be valued at $9.1 billion by 2025 and is expected to witness a CAGR of 9.15%. A rise in incidence of structural heart diseases (aortic stenosis and mitral regurgitation), technological advancements, the development of innovative repair devices — such as annuloplasty rings and occluders — and an increase in the demand for minimally-invasive techniques are factors driving the market.
Recent Developments
In June 2023, Teleflex received FDA 510(k) clearance for the Arrow EZ-IO Needle. The EZ-IO Needle, a critical component of the Arrow EZ-IO Intraosseous Vascular Access System, has a patented diamond tip designed for fast, precise and steady insertion. The EZ-IO System can be used when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases.
In May 20203, Teleflex presented new research findings reinforcing the long-term durability of Prostatic Urethral Lift (PUL) with the UroLift System and lower complication rates compared to other minimally invasive procedures for men with enlarged prostate, also called benign prostatic hyperplasia (BPH).
Price Performance
Shares of the company have dropped 11.2% in the past year compared with the industry’s fall of 4.5%.
Zacks Rank and Key Picks
Teleflex carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Addus Homecare Corporation (ADUS - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Hologic, Inc. (HOLX - Free Report) .
The Zacks Consensus Estimate for Addus Homecare’s 2023 earnings indicates a 10.9% year-over-year growth. The Zacks Consensus Estimate for ADUS’s 2023 earnings has moved 0.5% north in the past 30 days.
Addus Homecare has a long-term estimated growth rate of 11.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical reported a first-quarter 2023 adjusted EPS of 64 cents, beating the Zacks Consensus Estimate by 16.4%. Revenues of $297.6 million surpassed the Zacks Consensus Estimate by 5.9%. It currently carries a Zacks Rank #2.
Merit Medical has a long-term estimated growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average being 27.3%.
Hologic has gained 6.9% compared with the industry’s 4.4% rise in the past year.